Clinical Update For Decapeptyl® 6-Month Formulation in Advanced Prostate Cancer (Euronext, 12 February 2008)

14 Feb 2008

Ipsen have announced that its partner Debiopharm has presented the results of a phase III study with its new 6-month formulation of Decapeptyl ®1, a luteinizing hormone releasing hormone agonist (LHRHa) for the treatment of advanced prostate cancer.